Total Payments
$22,285
2023 Payments
$1,150
Companies
4
Transactions
62
Payment Breakdown by Category
Consulting$21,538 (96.7%)
Other$500.00 (2.2%)
Food & Beverage$246.45 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $21,538 | 58 | 96.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $500.00 | 1 | 2.2% |
| Food and Beverage | $246.45 | 3 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $22,038 | 59 | $0 (2023) |
| Adamas Pharmaceuticals, Inc. | $119.05 | 1 | $0 (2018) |
| KCI USA, Inc | $102.93 | 1 | $0 (2017) |
| Organogenesis Inc. | $24.47 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $1,150 | 2 | NOVARTIS PHARMACEUTICALS CORPORATION ($1,150) |
| 2022 | $500.00 | 1 | Novartis Pharmaceuticals Corporation ($500.00) |
| 2021 | $20,388 | 56 | Novartis Pharmaceuticals Corporation ($20,388) |
| 2018 | $119.05 | 1 | Adamas Pharmaceuticals, Inc. ($119.05) |
| 2017 | $127.40 | 2 | KCI USA, Inc ($102.93) |
All Payment Transactions
62 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/14/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | MAYZENT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $500.00 | General |
| Category: Neurology | ||||||
| 02/24/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: Neurology | ||||||
| 10/16/2022 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/08/2021 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/08/2021 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $3.36 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2021 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2021 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $40.32 | General |
| Category: NEUROSCIENCE | ||||||
| 11/06/2021 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/06/2021 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $5.60 | General |
| Category: NEUROSCIENCE | ||||||
| 11/01/2021 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/01/2021 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $61.60 | General |
| Category: NEUROSCIENCE | ||||||
| 06/12/2021 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 06/03/2021 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 05/23/2021 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 05/22/2021 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 05/10/2021 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 04/29/2021 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 04/26/2021 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 04/09/2021 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| Category: NEUROSCIENCE | ||||||
| 04/09/2021 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $62.72 | General |
| Category: NEUROSCIENCE | ||||||
| 04/08/2021 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| Category: NEUROSCIENCE | ||||||
| 04/08/2021 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $110.88 | General |
| Category: NEUROSCIENCE | ||||||
| 04/02/2021 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| Category: NEUROSCIENCE | ||||||
| 04/01/2021 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $775.00 | General |
| Category: NEUROSCIENCE | ||||||
| 04/01/2021 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $354.48 | General |
| Category: NEUROSCIENCE | ||||||
About Dr. Lance Kreplick, MD
Dr. Lance Kreplick, MD is a Emergency Medicine healthcare provider based in Riverview, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083661441.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lance Kreplick, MD has received a total of $22,285 in payments from pharmaceutical and medical device companies, with $1,150 received in 2023. These payments were reported across 62 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($21,538).
Ad
Practice Information
- Specialty Emergency Medicine
- Location Riverview, FL
- Active Since 05/30/2006
- Last Updated 05/19/2023
- Taxonomy Code 207P00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1083661441
Products in Payments
- GILENYA (Drug) $11,839
- MAYZENT (Drug) $10,199
- GOCOVRI (Drug) $119.05
- BIOSORB (Device) $102.93
- Apligraf (Device) $24.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.